Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | PI4KA | P42356 | 1/20 | 0.32 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.32 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.32 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21347418 | 0.82 | MEN1 (0.31) | MEN1ALDH1A1KMT2A | |
| SCHEMBL19660823 | 0.81 | MEN1 (0.30) | MEN1ALDH1A1KMT2A | |
| SCHEMBL22434688 | 0.78 | — | — | |
| SCHEMBL17188925 | 0.78 | — | — | |
| SCHEMBL22434785 | 0.74 | ADORA2A (0.32) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL21871809 | 0.74 | PI4KA (0.32) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL24499630 | 0.74 | ADORA2A (0.35) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL22326732 | 0.73 | ADORA2A (0.34) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL23619303 | 0.73 | CDK1 (0.33) | CDK1CCNB1CCNE1CDK2 | |
| SCHEMBL22326759 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220160746-A1 | 3'3'-CYCLIC DINUCLEOTIDE ANALOGUE COMPRISING A CYCLOPENTANYL MODIFIED NUCLEOTIDE AS STING MODULATOR | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I (CZ) | 2022-05-26 | — | — | US | disclosed |
| US-20220033431-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | MERCK SHARP & DOHME CORP. (US) | 2022-02-03 | — | — | US | disclosed |
| US-20210137962-A9 | CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-05-13 | — | — | US | disclosed |
| US-10875880-B2 | Processes for preparing oligomers | SAREPTA THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200291096-A1 | BICYCLIC PEPTIDE LIGAND STING CONJUGATES AND USES THEREOF | Bicyclerd Limited (GB) | 2020-09-17 | — | — | US | disclosed |
| US-20200040020-A1 | PROCESSES FOR PREPARING OLIGOMERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-02-06 | — | — | US | disclosed |
| US-20190192549-A1 | CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICALS CO (JP) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033431-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | STING1, CGAS, IFNAR1 | ADORA2A 64/4885ADORA1 32/4885ADORA2B 132/4885 |
| US-20200040020-A1 | PROCESSES FOR PREPARING OLIGOMERS | NOP2, PCBP1, RNGTT | ADORA2A 4356/4885ADORA1 4299/4885ADORA2B 4345/4885 |
| US-20210137962-A9 | CYCLIC DINUCLEOTIDE | STING1, CGAS, MAVS | ADORA2A 317/4885ADORA1 407/4885ADORA2B 621/4885 |
| US-20220160746-A1 | 3'3'-CYCLIC DINUCLEOTIDE ANALOGUE COMPRISING A CYCLOPENTANYL MODIFIED NUCLEOTIDE AS STING MODULATOR | STING1, MAVS, CGAS | ADORA2A 652/4885ADORA1 1736/4885ADORA2B 1765/4885 |
| US-20200291096-A1 | BICYCLIC PEPTIDE LIGAND STING CONJUGATES AND USES THEREOF | STING1, BID, VIP | ADORA2A 1318/4885ADORA1 1740/4885ADORA2B 1933/4885 |
| US-20190192549-A1 | CYCLIC DINUCLEOTIDE | STING1, CGAS, MAVS | ADORA2A 317/4885ADORA1 407/4885ADORA2B 621/4885 |
| US-10875880-B2 | Processes for preparing oligomers | NOP2, PCBP1, RNGTT | ADORA2A 4356/4885ADORA1 4299/4885ADORA2B 4345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.